Trial · NCT03299244
Results by group35
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 35
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis | Cinacalcet | 66.2 | percentage of participants | ||
| Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis | Etelcalcetide | 71.9 | percentage of participants | ||
| Percentage of Participants With > 50% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase | Cinacalcet | 41.6 | percentage of participants | ||
| Percentage of Participants With > 50% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase | Etelcalcetide | 59.1 | percentage of participants | ||
| Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase - Superiority Analysis | Cinacalcet | 58.0 | percentage of participants | ||
| Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase - Superiority Analysis | Etelcalcetide | 66.3 | percentage of participants | ||
| Percent Change From Baseline in Mean Predialysis Corrected Calcium During the Efficacy Assessment Phase | Cinacalcet | -8.00 | Standard Error 0.50 | percent change | |
| Percent Change From Baseline in Mean Predialysis Corrected Calcium During the Efficacy Assessment Phase | Etelcalcetide | -10.69 | Standard Error 0.53 | percent change | |
| Percentage of Participants With Mean Predialysis Serum Phosphorus ≤ 4.5 mg/dL During the Efficacy Assessment Phase | Cinacalcet | 26.2 | percentage of participants | ||
| Percentage of Participants With Mean Predialysis Serum Phosphorus ≤ 4.5 mg/dL During the Efficacy Assessment Phase | Etelcalcetide | 29.1 | percentage of participants | ||
| Number of Participants With cCa < 8.3 mg/dL At Any Time During the Study | Cinacalcet | 245 | Participants | ||
| Number of Participants With cCa < 8.3 mg/dL At Any Time During the Study | Etelcalcetide | 273 | Participants | ||
| Number of Participants With cCa < 8.0 mg/dL At Any Time During the Study | Cinacalcet | 194 | Participants | ||
| Number of Participants With cCa < 8.0 mg/dL At Any Time During the Study | Etelcalcetide | 241 | Participants | ||
| Number of Participants With cCa < 7.5 mg/dL At Any Time During the Study | Cinacalcet | 61 | Participants | ||
| Number of Participants With cCa < 7.5 mg/dL At Any Time During the Study | Etelcalcetide | 109 | Participants | ||
| Number of Participants With Treatment-emergent Symptomatic Hypocalcemia During the Study | Cinacalcet | 15 | Participants | ||
| Number of Participants With Treatment-emergent Symptomatic Hypocalcemia During the Study | Etelcalcetide | 35 | Participants | ||
| Number of Participants Who Developed Antibodies to Etelcalcetide | Etelcalcetide | 18 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events | Cinacalcet | Any treatment-emergent adverse event (TEAE) | 303 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03299244/results